| Objective:To investigate the clinical value of new gastric cancer screening and scoring system in screening gastric cancer and precancerous changes.Methods:a total of 362 participants included health checkers and inpatients in the second affiliated hospital of Nanhua university,and Hengyang area early gastric cancer screening people from December2017 to December 2019.Clear the risk crowd of gastric cancer according to the 14C-UBT,past medical history,family history,and so on.Gastric cancer risk groups were grouped according to age,gender,Hp infection,PGR and G17,namely the new gastric cancer screening and scoring system.0-11 scores were divided into low-risk group,12-16 scores into medium-risk group,and 17-23 scores into high-risk group.There were the low-risk group of 151 people,the middle-risk group of 122 people,the high-risk group of 18 people and the non-gastric cancer risk group of71 people.The gastroscopy and examination results of each group were recorded.The data were analyzed by software SPSS22.0.The quantitative data were expressed by?x±s.The data are analyzed by independent sample T test.The count data were expressed by ratio.Chi-square test was used for inter-group comparison.In this study,a=0.05 was used as the test standard.Results:All the patients with gastric cancer were at risk crowd of gastric cancer.The detection rate of early gastric cancer and gastric cancer in the middle and high-risk group were 66.6%and 70.0%,the detection rate of atrophic gastritis and intestinal metaplasia were 71.4%and 67.7%,so gastric cancer,atrophic gastritis and intestinal metaplasia mainly distribute in the middle and high-risk groups of gastric cancer risk groups.The incidence of atrophic gastritis in the middle risk group and low risk group or non-gastric cancer risk group were compared,P<0.008,the difference was statistically significant.The incidence of atrophic gastritis among other groups was not statistically significant.There was a statistically significant difference in the incidence of intestinal metaplasia between non-gastric cancer risk group and high-risk group or medium-risk group（P=0.004）,while there was no statistically significant difference in the incidence of intestinal epithelial metaplasia between other groups.The new gastric cancer screening and scoring system score of atrophic gastritis mainly distributed within the scope of the（12.76±3.31）,and the score of people without gastric mucosa epithelial atrophy mainly distributed the scope of（10.33±4.241）,P<0.05,the difference was statistically significant.The new gastric cancer screening and scoring system score of patients with intestinal metaplasia and people with no intestinal epithelium mainly distributed within the scope of the（13.27±3.48）and（10.42±4.1）.the statistical differences（P<0.05）.Conclusions:1.The incidence of atrophic gastritis in the middle risk group is higher than that in the low risk group and non-gastric cancer risk group.2.The incidence of intestinal metaplasia is higher in the middle and high-risk group than in the non-gastric cancer risk group.3.Gastroscopy is highly recommended for patients with the score≥10 in the new gastric cancer screening and scoring system. |
PDF Full Text Request